Evidence map›Paper›PMID 18703117›Full record

ReviewBiochimica et biophysica acta2008

When 2+2=5: the origins and fates of aneuploid and tetraploid cells.

Randall W King

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. [Pathogenesis and treatment progression of myelodysplastic syndrome combined with BehçetZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Randall W KingDepartment of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA. randy_king@hms.harvard.edu

Funding

Variation in Receptor Tyrosine Kinases and Breast Cancer RiskP50CA089393 · NCI · DANA-FARBER CANCER INSTITUTE · PI WINER, ERIC P · 2000 to 2009
$28.8M
Chemical Genetic Studies of MitosisR01GM066492 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KING, RANDALL W · 2002 to 2016
$4.7M
Chemical Genetic and Biochmechical Studies of Mitotic ProteolysisR56GM066492 · NIGMS · HARVARD MEDICAL SCHOOL · PI KING, RANDALL W · 2007 to 2007
$198k
NCI NIH HHS CA089393NCI NIH HHS P50 CA089393NIGMS NIH HHS GM 66492NIGMS NIH HHS R01 GM066492NIGMS NIH HHS R56 GM066492
6 · The paper itself

Abstract

Aneuploid cells are frequently observed in human tumors, suggesting that aneuploidy may play an important role in the development of cancer. In this review, I discuss the processes that may give rise to aneuploid cells in normal tissue and in tumors. Aneuploid cells may arise directly from diploid cells through errors in chromosome segregation, as a consequence of incorrect microtubule-kinetochore attachments, or through failure of the spindle checkpoint. A second route to formation of aneuploid cells is through a tetraploid intermediate, where division of tetraploid cells can yield very high rates of chromosome missegregation as a consequence of multipolar spindle formation. Diploid cells may become tetraploid through a variety of mechanisms, including endoreduplication, cell fusion, and cytokinesis failure. Although aneuploid cells may arise from either diploid or tetraploid cells, the fate of the resulting aneuploid cells may be distinct. It is therefore important to understand the different pathways that can give rise to aneuploid cells, and how the varied origins of these cells affect their subsequent ability to survive or proliferate.

Indexed as

AneuploidyChromosome SegregationPolyploidyAnimalsCell Cycle ProteinsCentrosomeChromosomal Proteins, Non-HistoneCytokinesisDNA ReplicationHumansMad2 ProteinsMiceNondisjunction, GeneticNuclear Matrix-Associated ProteinsNuclear ProteinsNucleocytoplasmic Transport ProteinsBub1 spindle checkpoint proteinBub3 protein, mouseCell Cycle Proteinscentromere protein EChromosomal Proteins, Non-HistoneMad2l2 protein, mouseMad2 ProteinsNuclear Matrix-Associated ProteinsNuclear ProteinsNucleocytoplasmic Transport ProteinsPoly-ADP-Ribose Binding ProteinsProtein Serine-Threonine KinasesRae1 protein, mouse

Identifiers

PMID18703117
PMCPMC2581926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.